The rate of macrolide resistance among Streptococcus pneumoniae is increasing, but some investigators have questioned its clinical relevance. We conducted a matched case-control study of patients with bacteremic pneumococcal infection at 4 hospitals to determine whether development of breakthrough bacteremia during macrolide treatment was related to macrolide susceptibility of the pneumococcal isolate. Case patients (n p ) were patients who had pneumococcal bacteremia and an isolate that was either resistant or intermediately 86 resistant to erythromycin. Controls ( ) were patients matched for age, sex, location, and year that n p 141 bacteremia developed who had an erythromycin-susceptible pneumococcus isolated. Excluding patients with meningitis, 18 (24%) of 76 case patients and none of 136 matched controls were taking a macrolide when blood was obtained for culture ( ). Moreover, 5 (24%) of 21 case patients with the low-P p .00000012 level-resistant M phenotype and none of 40 controls were taking a macrolide ( ). These data show P p .00157 that development of breakthrough bacteremia during macrolide or azalide therapy is more likely to occur among patients infected with an erythromycin-resistant pneumococcus, and they also indicate that in vitro macrolide resistance resulting from both the efflux and methylase mechanisms is clinically relevant.
pathogens, such as Mycoplasma, Chlamydia, and Legionella species. Furthermore, the newer macrolide antibiotics have improved in vitro activity against Haemophilus influenzae. For all of these reasons, some authorities have recommended the use of macrolides for the empirical treatment of outpatients with community-acquired pneumonia. In fact, guidelines from the American Thoracic Society, the Infectious Diseases Society of America, and others consider macrolides to be first-line agents for the empirical treatment of outpatients with community-acquired pneumonia [1] [2] [3] [4] .
Macrolide resistance among pneumococci is increasing in the United States and Spain and in other parts of the world [5, 6] . Furthermore, macrolide resistance is more frequent among penicillin-resistant pneumoDownloaded from https://academic.oup.com/cid/article-abstract/35/5/556/445800 by guest on 17 December 2018 cocci [7] . Macrolide resistance is mediated by ribosomal modification or active drug efflux. The former, when caused by methylation of rRNA, is associated with high-level resistance to macrolides, lincosamides, and streptogramin type B antibiotics (MLS b phenotype), whereas the latter is associated with lower levels of resistance to 14-and 15-membered macrolides (M phenotype) [8, 9] . In addition to methylation, other ribosomal modifications include mutations in 23S rRNA and ribosomal protein L4 [10] . Ribosomal methylation is the predominant mechanism of erythromycin resistance in isolates in Spain [11] , whereas efflux is the predominant mechanism in isolates in the United States [12] . The increased prevalence of isolates with erythromycin resistance in the United States is caused by the increased number of isolates with the efflux mechanism [12] . Despite numerous reports of in vitro resistance [5, 6] , there is limited information on the clinical relevance of macrolide resistance among pneumococci. In fact, some investigators have questioned the clinical relevance of in vitro macrolide resistance [12] [13] [14] [15] [16] . Although a few case reports have documented clinical failures associated with macrolides and azalides, the clinical impact of this resistance remains controversial [17, 18] .
Erythromycin-resistant pneumococcal bacteremia has developed in adults and children while they were receiving a macrolide antibiotic (usually orally) [19] [20] [21] [22] [23] . Possible reasons for clinical failure of treatment with macrolides include poor compliance, poor absorption, or antimicrobial resistance. We performed a case-control study to determine whether the development of pneumococcal bacteremia during macrolide therapy was more common among patients with erythromycin-resistant pneumococci than among patients with erythromycin-susceptible pneumococci.
METHODS

Hospitals.
The Hospital Mú tua de Terrassa is a 500-bed, acute-care referral teaching hospital with ∼23,000 discharges per year in Terrassa, a city in the province of Barcelona, Spain. A prospective surveillance program for all patients with pneumococcal bacteremia was initiated in 1988. Data on antibiotic susceptibility, determined by broth microdilution as described by the National Committee for Clinical Laboratory Standards (NCCLS), and patient demographic data were available for the period from 1 January 1989 through 31 March 2000.
The Miriam Hospital is a 247-bed, adult medical-surgical hospital with ∼12,000 discharges per year, and the Rhode Island Hospital is a 719-bed general hospital without obstetric services that has ∼30,000 discharges per year. Both are acutecare tertiary referral teaching hospitals in Providence, Rhode Island. Brigham and Women's Hospital is a 702-bed, acutecare tertiary referral teaching hospital in Boston that does not have pediatric services.
The clinical microbiology laboratories of the Miriam and Brigham and Women's Hospitals determined the erythromycin susceptibility of all pneumococcal blood isolates by disk diffusion as described by the NCCLS. Results were stored in a WHONET database (microbiology laboratory database software; World Health Organization). Complete data on antibiotic susceptibility and patient demographics were available for the period from 1 January 1987 through 31 December 1999 at the Miriam Hospital and for the period from 1 July 1987 through 31 December 1999 at Brigham and Women's Hospital.
At Rhode Island Hospital, all pneumococcal blood isolates were stored in a frozen state. Susceptibility to erythromycin and clindamycin was determined by disk diffusion as described by the NCCLS. The isolates that were tested were recovered from patients who had bacteremia that developed between 1 January 1997 and 31 December 1997.
NCCLS criteria were used to categorize the isolates [24, 25] . In the present study, isolates categorized as either intermediately resistant or resistant to macrolides were considered "macrolidenonsusceptible" isolates.
Matched case-control study. "Case patients" were patients with bacteremia due to a macrolide-nonsusceptible pneumococcus, and "controls" were patients with bacteremia due to a macrolide-susceptible pneumococcus. A review of susceptibility data from the 4 hospitals identified 90 potential case patients. Controls were matched to case patients for hospital, sex, age group (0-17, 18-44, 45-64, and у65 years), and the year that bacteremia developed. Eight neonates (1 with a macrolide-resistant pneumococcus and 7 with a macrolide-susceptible pneumococcus) were excluded from the matched case-control study.
Using a standard form, we collected data from the medical records of case patients and controls. The institutional review board at Brigham and Women's Hospital approved the medical record review for patients at their hospital. The data collected included whether the patients were taking a macrolide antibiotic at the time that blood was obtained for culture, including the antibiotic dose and its frequency, route, and duration of administration. In addition, we collected data on patient demographics, predisposing medical conditions, type of infection, antibiotic treatment, in-hospital mortality, and the antibiotic susceptibility of the infecting pneumococcal isolate [26] .
Microbiological studies of isolates recovered from patients who had treatment failure. We confirmed the susceptibilities of isolates recovered from patients with macrolide treatment failure by determining the erythromycin and clindamycin MICs by means of the microdilution broth method with MuellerHinton broth supplemented with 3% lysed horse blood, using NCCLS methods [25] . The presence of erm and mef genes was determined using PCR [27] . Statistical analysis. Case patients and controls were compared for binary variables with use of a variable-ratio matching z score [28] . A modified Student's t test, with each doubly matched control counted as half an observation, was used for continuous-variable comparisons. The site of infection was not known before medical records were reviewed. Because macrolides are not appropriate therapy for pneumococcal meningitis, a separate analysis was done after excluding patients with meningitis (10 case patients and 5 controls). Using the test or Fisher's exact test, we compared the categorical var-2 x iables for those who were or were not taking a macrolide antibiotic within the group of patients with erythromycin-resistant pneumococci (i.e., the case patients). (table 2) . Only 0.4% of pneumococci isolated from patients 45-64 years of age were resistant to erythromycin.
RESULTS
Rate
Matched case-control study. For 57 case patients, 2 matched control patients were available. For 30 case patients, 1 matched control patient was available; to obtain a match for 8 of these case patients, we assigned a single control whose isolate was recovered during an adjacent calendar year and, for 3 of these case patients, we assigned a single control of the opposite sex. Two case patients were excluded from the analysis because their medical records could not be found.
Two HIV-infected patients, one with bacteremia due to an erythromycin-susceptible pneumococcus and the other with bacteremia due to an erythromycin-nonsusceptible pneumococcus, were excluded after review of their medical records, which revealed that they took prophylactic azithromycin, 1200 mg once a week. They were excluded because they were not taking azithromycin dosages used for the treatment of acute pneumococcal infection. Furthermore, the date of the last dose taken by each patient was not documented.
Case patients and controls were similar demographically (table 3). The mean age was 51.8 years (range, 0-95 years) for case patients and 55.2 years (range, 0-97 years) for controls ( ). Among those patients for whom information on P p .9434 race was available (91%), blacks were less likely than whites to have an erythromycin-nonsusceptible pneumococcus isolated ( ). Case patients were more likely than controls to P p .0153 have meningitis ( ). Nineteen (22%) of the 86 case P p .0059 patients with macrolide-resistant pneumococcal bacteremia were taking a macrolide antibiotic when blood was obtained for culture, whereas none of the 141 control patients were taking a macrolide antibiotic at this time (
). P p .00000004 When patients with meningitis were excluded from the analysis, 18 (24%) of 76 case patients and none of the 136 controls were found to be taking a macrolide antibiotic at the time that blood samples were obtained for culture (z p ; ). Also, blacks were less likely to have 5.2915 P p .0000001213 an erythromycin-resistant pneumococcus ( ; z p Ϫ2.4254 P p ). Asplenia was more common among case patients (5 of .0153 76 case patients) than among controls (2 of 136 controls) ( ; ) . z p 2.4121 P p .0159
When only data for bacteremic case patients with the less resistant M phenotype were analyzed, 6 (21%) of 28 case patients and none of 52 controls were found to be taking a macrolide ( ; ). When patients with meningitis z p 3.464 P p .00053 were excluded, 5 (24%) of 21 case patients and none of 40 Of the 19 patients who were receiving macrolide therapy at the time that pneumococcal bacteremia developed, 9 adults had pneumonia, 2 had pneumonia with empyema, 1 had pneumonia and meningitis, and 1 had no site identified. Three of the children, who were 1-2 years of age, had pneumonia, and 3 had no identified type of infection.
Comparison of case patients taking a macrolide with those not taking a macrolide at the time that blood was obtained for culture. No deaths occurred among case patients who had pneumococcal bacteremia develop while they were receiving macrolide therapy (table 4) . Of interest, among case patients who did not take a macrolide, the mortality rate was 18%, but this rate was not statistically different from the mortality rate among case patients who did take a macrolide ( ). P p .0605 Case patients who did not take a macrolide were older than those who did ( ). Their other characteristics were P p .0394 similar.
Type of macrolide or azalide taken by case patients. Patients were taking erythromycin, azithromycin, clarithromycin, and josamycin while they were bacteremic (table 5). All patients were taking monotherapy, except for 1 patient who received both erythromycin and azithromycin. The average duration of antibiotic therapy was 3.9 days. One patient took clarithromycin for 130 days for possible treatment of his multiple myeloma and was not included in the calculation of the average duration of antibiotic therapy. A total of 18 patients initially received outpatient treatment with orally administered macrolides.
Case report. A 28-year-old man developed a respiratory tract infection, and treatment with orally administered penicillin was prescribed. After the patient took the penicillin for 1.5 weeks, his condition worsened and he went to the hospital, where chest radiography showed an infiltrate. Blood cultures showed no growth; the patient took penicillin a few hours before presenting to the hospital. He was given azithromycin, 500 mg iv; several hours later, he was given erythromycin, 1000 mg iv. Culture of blood samples obtained ∼3 h and 8 h, respectively, after administration of the erythromycin and azithromycin doses yielded pneumococci that were resistant to erythromycin (MIC, 4 mg/mL; mef gene) and intermediately resistant to penicillin (MIC, 0.25 mg/mL). Cefuroxime, 750 mg iv, was given after blood samples were obtained for culture. The next day, he received two 1000-mg doses of erythromycin intravenously, one 750-mg dose of cefuroxime intravenously, and 500 mg of azithromycin orally. On the third day of hospitalization, the patient received 250 mg of azithromycin orally. He improved (his fever resolved and his WBC count decreased from 12,200 cells/mm 3 to 9800 cells/mm 3 ) and was sent home while receiving treatment with orally administered azithromycin.
The patient returned to the hospital 2 days after discharge because he felt worse. Blood cultures again yielded erythromycin-resistant pneumococci (MIC, 4 mg/mL; mef gene). He was given ceftriaxone intravenously, subsequently experienced improvement in his condition, and went home after 15 days of therapy. Two months after discharge from the hospital, the patient was well.
Microbiologic findings for isolates recovered from patients with macrolide treatment failure. Among isolates available for genetic testing, 10 isolates from Spain had the erm gene, whereas 3 of 4 isolates from the United States had the mef gene and 1 had the erm gene. Three other isolates from the United States were susceptible to clindamycin, a finding consistent with the M phenotype typical of mef-mediated resistance (table 5).
All of the isolates with the erm gene had high-level resistance to erythromycin (table 5). The isolates with the mef gene had erythromycin MICs that varied depending on the testing conditions. Two isolates had erythromycin MICs of 4 and 16 mg/ mL in ambient air and MICs of 8 and 64 mg/mL in an atmosphere that was 5% carbon dioxide, according to the microdilution broth method. One isolate did not grow when tested in ambient air. In a 5% carbon dioxide atmosphere, it had an erythromycin MIC that was 16 mg/mL by the microdilution broth method (in this study) and 32 mg/mL by the agar dilution method [19] . Penicillin MICs were determined for 17 isolates. Three had MICs of р0.06 mg/mL (susceptible), 10 had MICs of 0.12-1.0 mg/mL (intermediately resistant), and 4 had MICs of 1.5-2.0 mg/mL (resistant). One isolate was found to be susceptible to penicillin by the oxacillin disk method (32 mm), and 1 had no zone of inhibition (6 mm).
The pneumococci isolated from patients with failure of macrolide therapy were of various capsular polysaccharide types (table 5) .
Curative treatment received in the hospital. Eighteen of the 19 patients were treated with a b-lactam antibiotic (cefuroxime, cefotaxime, ceftriaxone, ampicillin, penicillin) given intravenously. One patient, who was allergic to penicillin and cephalexin, was treated with intravenously administered vancomycin. All patients responded to the antibiotics that they received in the hospital and were discharged with an improved condition.
DISCUSSION
The pneumococcus is both a colonizer and a pathogen of the respiratory tract. When the organism is isolated from sputum culture, it may be difficult to determine whether it is causing infection. However, when the organism is isolated from the bloodstream, it is virtually certain to be the cause of invasive disease. Some children who appear to be healthy can have pneumococcal bacteremia that resolves without antibiotic treatment; however, this occurs very rarely in adults [29] . Three children in the present study had no apparent source of bacteremia. The conditions of 2 of these children, one of whom had pharyngitis and one of whom had possible otitis media, worsened clinically while the children were taking a macrolide antibiotic. The third child had intermittent fever for 2 weeks; the fever persisted despite administration of cefaclor (for 10 days), followed by josamycin (for 4 days). All 3 children were admitted to the hospital and showed improvement in their conditions when they were treated with a b-lactam antibiotic.
We have described the therapeutic failure of macrolides in the treatment of 19 patients with bacteremia caused by nonsusceptible isolates of S. pneumoniae. The conditions of these patients either failed to improve or clinically worsened, and blood culture results were positive during therapy, regardless of the macrolide or azalide used. Hyde et al. [12] reported that (1) the in vitro rate of macrolide resistance among pneumococci from the United States increased from 10.6% in 1995 to 20.4% in 1999, and (2) the median erythromycin MIC of the M phenotype strains doubled during that time. Hyde et al. [12] emphasized, however, that more data documenting the clinical relevance of low-level macrolide resistance are needed. In the present study, breakthrough bacteremias were due to pneumococci with erythromycin nonsusceptibility resulting from either efflux (mef-mediated) or ribosomal modification (erm-mediated). All isolates that contained the erm gene had an erythromycin MIC of у64 mg/mL, whereas the erythromycin MIC for isolates that contained the mef gene was 4-64 mg/mL, depending on the method and conditions of testing. Erythromycin MICs were 2-4 times higher when tested in a 5% carbon dioxide atmosphere, an effect previously noted elsewhere [30] .
Some investigators have hypothesized that the high intracellular concentrations of azalides and some macrolides would overcome the moderate levels of macrolide resistance determined by the mef gene [13, 15, 16] . There is only one published report in which treatment with a macrolide or an azalide failed for a patient with a strain demonstrated to contain the mef gene (azithromycin MIC, 8 mg/mL) [20] ; however, in 4 other reports of treatment failure, the strains had the erythromycinresistant/clindamycin-susceptible M phenotype, consistent with mef [21, 22] . In the present study, treatment failures occurred in patients infected with pneumococci that had erythromycin MICs as low as 4 mg/mL, as mediated by the mef gene. These findings are in agreement with data from animal models showing that clarithromycin and azithromycin were not effective in the treatment of mice and rats infected with macrolide-resistant pneumococci (clarithromycin MIC, 4 mg/mL) that contained the mef gene [31] . They also support NCCLS criteria that categorize isolates as intermediately resistant if the MIC is 0.5 mg/ mL and resistant if the MIC is у1 mg/mL.
Despite the use of the proper dose, treatment failure can occur because an antibiotic is either not taken or not absorbed or because the infecting bacterium is resistant to the antibiotic. Problems with compliance and absorption should have occurred equally among controls with erythromycin-susceptible pneumococcal bacteremia and among case patients. Our finding that none of the control patients ( ) was taking a n p 141 macrolide antibiotic at the time that blood samples were obtained for culture makes it appear unlikely that the 19 treatment failures occurred solely because of nonadherence or poor absorption. Moreover, one of the patients in this study received azithromycin and erythromycin intravenously, obviating the possibility of nonadherence and poor absorption. Similarly, Waterer et al. [32] reported a case in which a patient's clinical condition worsened while the patient was receiving azithromycin intravenously and for which blood culture yielded an erythromycin-resistant pneumococcus (MIC, 16 mg/mL).
Other than taking a macrolide antibiotic, the only other characteristic that differed between case patients and matched controls was race. Blacks were less likely than whites to have an erythromycin-nonsusceptible pneumococcus. Pneumococci isolated from whites have been noted to be more resistant to antibiotics, presumably because whites are more likely to obtain outpatient medical care and receive antibiotics [33] .
The mortality rate tended to be lower among case patients taking macrolides than among patients not taking a macrolide (0 versus 18%; ), a curious finding. Those who were P p .06 taking macrolides were younger (mean age, 40 vs. 55 years;
), were less likely to have meningitis (5% vs. 13%), P p .0394 and took an antibiotic for an average of 3.9 days before hospitalization. We calculated the expected mortality rate among the 2 groups of patients on the basis of published age-specific case-fatality rates [34] . The expected number of deaths was 1.9 among those taking a macrolide and 8.4 among those not taking a macrolide. Hence, this curious finding seems to have occurred because physicians are more likely to give orally administered macrolides to younger and less sick patients, whereas older and sicker patients are more likely to be admitted to the hospital immediately to receive parenteral antibiotics.
It should be of no surprise that so few cases of failure of macrolide treatment among patients with macrolide-nonsusceptible pneumococcal infections have been recorded. The cases described are the "tip of an iceberg." Some patients with milder disease show improvement without antibiotic treatment [35] . Others are very ill and receive parenteral antibiotics, usually a combination of agents [26] . For breakthrough bacteremia to occur because of resistance, the patient must be infected with a resistant isolate and must receive treatment with an oral macrolide antibiotic. This explains, in part, why it has taken 38 hospital-years of data collection and review to document these treatment failures. The use of a standardized computer database that links clinical, demographic, and microbiological data and information on antibiotic use from multiple hospitals would facilitate this kind of analysis. Indeed, it might make it possible to do it prospectively, in real time.
We report an association between macrolide resistance and bacteremia during macrolide treatment. Commonly used guidelines for the treatment of adult outpatients with community-acquired pneumonia include administration of a macrolide as one of the first-line drugs [1] [2] [3] [4] . This may be inappropriate in areas with a high incidence of resistance to these agents. Guidelines in the United States and Canada, in contrast to those from several European countries [36] , tend to give greater weight to coverage of atypical pathogens than to optimum coverage of S. pneumoniae. We believe our data favor European-type guidelines, which recommend the use of high-dose orally administered amoxicillin for outpatients with mild-to-moderate community-acquired pneumonia and which reserve coverage of atypical pathogens with macrolides for selected high-risk populations.
